Pretreatment cystatin C in children with malignancy: Can it predict chemotherapy-induced glomerular filtration rate reduction during the induction phase?

Journal of Pediatric Hematology/Oncology

Volumn 26, Issue 6, 2004, Pages 336-341

  Al Tonbary, Youssef A ^a,b   Hammad, Ayman M ^a,b   Zaghloul, Hamed M ^b   El Sayed, Hazem E ^b   Abu Hashem, Ekbal ^a  

^a MANSOURA UNIVERSITY   (Egypt)

^b MANSOURA UNIVERSITY CHILDREN S HOSPITAL   (Egypt)

Author keywords

Chemotherapy; Children; Cystatin C; Nephrotoxicity

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARAGINASE; BIOLOGICAL MARKER; CISPLATIN; CREATININE; CYCLOPHOSPHAMIDE; CYSTATIN C; CYTARABINE; DAUNORUBICIN; METHOTREXATE; PREDNISONE; VINCRISTINE;

ACCURACY; ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BLOOD LEVEL; CANCER CHEMOTHERAPY; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG INDUCED DISEASE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; MALE; NEPHROBLASTOMA; NEPHROTOXICITY; NONHODGKIN LYMPHOMA; PATIENT MONITORING; PREDICTION; PRIORITY JOURNAL;

ADOLESCENT; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; CREATININE; CYSTATINS; CYSTEINE PROTEINASE INHIBITORS; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; MALE; NEOPLASMS; RETROSPECTIVE STUDIES; ROC CURVE;

EID: 2942620199     PISSN: 10774114     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-200406000-00002     Document Type: Article

References (44)

1. Andoh TF, Burdmann EA, Bennett WM. Nephrotoxicity of immunosuppressive therapy drugs: experimental and clinical observations. Semin Nephrol. 1997;17:34-41.
2. Kintzel PE. Anticancer drug-induced kidney disorders. Incidence, prevention and management. Drug Saf. 2001;24:19-38.
3. Kopecna L. Late effects of anticancer therapy on kidney function in children with acute lymphoblastic leukemia. Bratisl Leuk Listy. 2001;102: 357-360.
4. Patterson WP, Reams GP. Renal toxicities of chemotherapy. Semin Oncol. 1992;19:521-528.
5. Kasiske BL, Keane WF. Laboratory assessment of renal disease: clearance, urinalysis and renal biopsy. In: Brenner BM, Rector FC, eds. The Kidney. Philadelphia: Saunders; 1996:1137-1173.
6. Perrone RD, Madias NE, Levy AS. Serum creatinine as an index of renal function: new insights into old concepts. Clin Chem. 1992;38:1933-1953.
7. Barrett AJ, Davies ME, Grubb A. The place of human gamma-trace (cystatin C) amongst the cysteine proteinase inhibitors. Biochem Biophys Res Commun. 1984;120:631-636.
8. Grubb A, Lofberg H. Human gamma trace structure function and clinical use of concentration measurements. Scand J Clin Lab Invest. 1985;45: 7-13.
9. Grubb A. Diagnostic value of analysis of cystatin C and protein HC in biological fluids. Clin Nephrol. 1992;38:S20-S27.
10. Nilsson-Ehle P, Grubb. A. New markers for determination of GFR: iohexol clearance and cystatin C serum concentration. Kidney Int. 1994;47: S17-S19.
11. 2-imcroglobulin better markers than serum creatinine for prediction of a normal GFR in pediatric subjects? Clin Chim. 1997;43:1077-1078.
12. Bokenkamp A, Domanetzki M, Zinck R, et al. Cystatin C: a new marker of GFR in children independent of age and height. Pediatrics. 1998;101: 875-881.
13. Jung K, Jung M, Cystatin C. A promising marker of glomerular filtration rate to replace creatinine. Nephron. 1995;70:370-371.
14. Newman DJ, Thakkar H, Edwards RG, et al. Serum cystatin C measured by automated immunoassay: a more sensitive marker of changes in GFR than serum creatinine. Kidney Int. 1995;47:312-318.
15. Helin I, Axenram M, Grubb A. Serum cystatin C as a determinant of GFR in children. Clin Nephrol. 1998;49:221-225.
16. Riehm H, Gadner H, Henze G, et al. Results and significance of six randomized trials in four consecutive ALL-BFM studies. Haematol Blood Transfus. 1990;33:439-450.
17. Anderson JR, Wilson JF, Jenkin DT, et al. Childhood non-Hodgkin's lymphoma. The results of a randomized therapeutic trial comparing a 4-drug regimen (COMP) with a 10-drug regimen (LSA2-L2). N Engl J Med. 1983;308:559-565.
18. Shafford E, Rogers D, Pritchard J. Advanced neuroblastoma: improved response rate using a multiagent regimen (OPEC II) including sequential cisplatin and VM-26. J Clin Oncol. 1984;2:742-747.
19. Bartels H, Bohmer M. Micro-determination of creatinine. Clin Chim Acta. 1971;32:81-85.
20. Kyhse-Andersen J, Schmidt C, Nordin G, et al. Serum cystatin C, determined by a rapid, automated particle enhanced turbidimetric method, is a better marker than serum creatinine for GFR. Clin Chem. 1994;40:921-926.
21. Schwartz GJ, Brion LP, Spitzer A. The use of plasma creatinine concentration for estimation GFR in infants, children and adolescents. Pediatr Clin North Am. 1987;34:571-590.
22. Breen D, Bihari D. Acute renal failure as a part of multiple organ failure: the slippery slope of critical illness. Kidney Int. 1998;66:S25-S33.
23. Ries F, Klastersky J. Nephrotoxicity induced by chemotherapy with special emphasis on cisplatin toxicity. Am J Kidney Dis. 1986;8:368-379.
24. Womer RB, Pritchard J, Barratt TM. Renal toxicity of cisplatin in children. J Pediatr. 1985;106:659-663.
25. Daugaard G, Rossing N, Rorth M. Effects of cisplatin on different measures of glomerular function in the human kidney with special emphasis on high dose. Cancer Chemother Pharmacol. 1988;21:163-167.
26. Frei E 3rd, Jaffe N, Tattersall MH, et al. New approaches to cancer chemotherapy with methotrexate. N Engl J Med. 1975;292:846-851.
27. Weinblatt ME. Toxicity of low-dose methotrexate in rheumatoid arthritis. J Rheumatol. 1985;12:(S12):35-39.
28. Hall RL, Wilke WL, Fettman MJ. The progression of Adriamycin-induced nephrotic syndrome in rats and the effect of captopril. Toxicol Appl Pharmacol. 1986;82:164-174.
29. Okuda S, Oh Y, Tsuruda H, et al. Adriamycin-induced nephropathy as a model of chronic progressive glomerular disease. Kidney Int. 1986;29: 502-510.
30. Grond J, Weening JJ, Van Goor H, et al. Application of puromycin aminonucleoside and Adriamycin to induce chronic renal failure in the rat. Contrib Nephrol. 1988;60:83-93.
31. Scholey JW, Miller PL, Rennke HG, et al. Effect of converting enzyme inhibition on the course of Adriamycin-induced nephropathy. Kidney Int. 1989;36:816-822.
32. Rabadi SJ, Khandekar JD, Miller H. J. Mitomycin-induced hemolytic uremic syndrome: case presentation and review of the literature. Cancer Treat Rep. 1982;66:1244-1247.
33. Cantrell JE, Phillips TM, Schein PS. Carcinoma-associated hemolytic-uremic syndrome: a complication of mitomycin C chemotherapy. J Clin Oncol. 1985;3:723-734.
34. Lesesne JB, Rothschild N, Erickson B, et al. Cancer-associated hemolytic-uremic syndrome: analysis of 85 cases from a national registry. J Clin Oncol. 1989;7:781-789.
35. Loebstein R, Atanackovic G, Bishai R, et al. Risk factors for long-term outcome of ifosfamide-induced nephrotoxicity in children. J Clin Pharmacol. 1999;39:454-461.
36. Abrahamson M, Olafsson I, Palsdottir A, et al. Structure and expression of the human cystatin C gene. Biochem J. 1990;268:287-294.
37. Sloane BF. Suicidal tumor proteases. Nat Biotechnol. 1996;14:826-827.
38. Stabuc B, Vrhovec L, Stabuc-Silih M, et al. Improved prediction of decreased creatinine clearance by serum cystatin C: use in cancer patients before and during chemotherapy. Clin Chem. 2000;46:193-197.
39. Giovannetti S, Barsotti G. In defense of creatinine clearance. Nephron. 1991;59:11-14.
40. Walser M. Assessing renal function from creatinine measurements in adults with chronic renal failure. Am J Kidney Dis. 1998;32:23-31.
41. Lemann J, Bidani AK, Bain RB, et al. Use of serum creatinine to estimate GFR in health and early diabetic nephropathy. Collaborative Study Group of Angiotensin-Converting Enzyme Inhibition in Diabetic Nephropathy. Am J Kidney Dis. 1990;16:236-243.
42. Coresh J, Toto RD, Kirk KA, et al. Creatinine clearance as a measure of GFR in screenees for the African-American Study of Kidney Disease and Hypertension Pilot study. Am J Kidney Dis. 1998;32:32-42.
43. Donckerwolcke RA, Coppes MJ. Cytotoxic treatment and alterations in kidney function. Med Pediatr Oncol. 1998;30:178-179.
44. Prasad VK, Lewis IJ, Aparicio SR, et al. Progressive glomerular toxicity of ifosfamide in children. Med Pediatr Oncol. 1996;27:149-155.